Literature DB >> 15369449

Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease.

Ruth Foley1, Donal Hollywood, Mark Lawler.   

Abstract

Microarray technology has recently accelerated the study of the molecular events involved in prostate cancer, offering the prospect of more precise prognosis and new therapeutic strategies. This review summarises current knowledge of the molecular pathology of prostate cancer. The expression and function of numerous genes have been shown to be altered in prostate cancer. Many of these genes are involved in cell cycle regulation, steroid hormone metabolism or regulation of gene expression. The mechanisms by which androgen independence arises are discussed, including cross-activation, gene amplification and point mutations of the androgen receptor. Analysis of changes in the levels of expression of large numbers of genes during prostate cancer progression have provided a better understanding of the basis of the disease, yielding new molecular markers, such as hepsin, with potential use in diagnosis and prognosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15369449     DOI: 10.1677/erc.1.00699

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  12 in total

Review 1.  Specific targeting of gene therapy to prostate cancer using a two-step transcriptional amplification system.

Authors:  Marxa L Figueiredo; Makoto Sato; Mai Johnson; Lily Wu
Journal:  Future Oncol       Date:  2006-06       Impact factor: 3.404

2.  Are GSTM1, GSTT1 and CAG repeat length of androgen receptor gene polymorphisms associated with risk of prostate cancer in Iranian patients?

Authors:  Zahra Ousati Ashtiani; Sayed-Mohammad Hasheminasab; Mohsen Ayati; Bareto Sabah Goulian; Mohammad Hossein Modarressi
Journal:  Pathol Oncol Res       Date:  2010-11-19       Impact factor: 3.201

3.  The relationship between CAG repeat length polymorphism and infertility in Southern Chinese Han women.

Authors:  D Tong; J Deng; H Sun; L Chen; X Wu
Journal:  J Endocrinol Invest       Date:  2010-02-24       Impact factor: 4.256

4.  XAF1 expression and regulatory effects of somatostatin on XAF1 in prostate cancer cells.

Authors:  Zhaoquan Xing; Zunlin Zhou; Rong Yu; Shuling Li; Chunde Li; Sten Nilsson; Zhaoxu Liu
Journal:  J Exp Clin Cancer Res       Date:  2010-12-11

5.  Prognostic factors in prostate cancer.

Authors:  A Buhmeida; S Pyrhönen; M Laato; Y Collan
Journal:  Diagn Pathol       Date:  2006-04-03       Impact factor: 2.644

6.  Transcriptomes of human prostate cells.

Authors:  Asa J Oudes; Dave S Campbell; Carrie M Sorensen; Laura S Walashek; Lawrence D True; Alvin Y Liu
Journal:  BMC Genomics       Date:  2006-04-25       Impact factor: 3.969

7.  URG11 Regulates Prostate Cancer Cell Proliferation, Migration, and Invasion.

Authors:  Bin Pan; Yunlin Ye; Haiping Liu; Jianli Zhen; Hongmei Zhou; Yutong Li; Lijun Qu; Youke Wu; Chuanrong Zeng; Weifeng Zhong
Journal:  Biomed Res Int       Date:  2018-05-31       Impact factor: 3.411

8.  Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression.

Authors:  Shivani Kamdar; Ruth Isserlin; Theodorus Van der Kwast; Alexandre R Zlotta; Gary D Bader; Neil E Fleshner; Bharati Bapat
Journal:  Clin Epigenetics       Date:  2019-03-27       Impact factor: 6.551

9.  Genetic polymorphisms of GSTM1, GSTT1, and GSTP1 with prostate cancer risk: a meta-analysis of 57 studies.

Authors:  Mancheng Gong; Wenjing Dong; Zhirong Shi; Yangyang Xu; Wenjun Ni; Ruihua An
Journal:  PLoS One       Date:  2012-11-26       Impact factor: 3.240

10.  Effects of AG490 and S3I-201 on regulation of the JAK/STAT3 signaling pathway in relation to angiogenesis in TRAIL-resistant prostate cancer cells in vitro.

Authors:  Venhar Gurbuz; Ece Konac; Nuray Varol; Akin Yilmaz; Serhat Gurocak; Sevda Menevse; Sinan Sozen
Journal:  Oncol Lett       Date:  2014-01-14       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.